These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 21870889

  • 41. Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.
    Dietrich M, Koska V, Hecker C, Göttle P, Hilla AM, Heskamp A, Lepka K, Issberner A, Hallenberger A, Baksmeier C, Steckel J, Balk L, Knier B, Korn T, Havla J, Martínez-Lapiscina EH, Solà-Valls N, Manogaran P, Olbert ED, Schippling S, Cruz-Herranz A, Yiu H, Button J, Caldito NG, von Gall C, Mausberg AK, Stettner M, Zimmermann HG, Paul F, Brandt AU, Küry P, Goebels N, Aktas O, Berndt C, Saidha S, Green AJ, Calabresi PA, Fischer D, Hartung HP, Albrecht P.
    Brain; 2020 Apr 01; 143(4):1127-1142. PubMed ID: 32293668
    [Abstract] [Full Text] [Related]

  • 42. Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations.
    Kolagar TA, Farzaneh M, Nikkar N, Khoshnam SE.
    Curr Stem Cell Res Ther; 2020 Apr 01; 15(2):102-110. PubMed ID: 31441732
    [Abstract] [Full Text] [Related]

  • 43. Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis.
    Balk LJ, Petzold A.
    Neurodegener Dis Manag; 2014 Apr 01; 4(2):165-76. PubMed ID: 24832034
    [Abstract] [Full Text] [Related]

  • 44. Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.
    Mueller SG, Schuff N, Weiner MW.
    NMR Biomed; 2006 Oct 01; 19(6):655-68. PubMed ID: 16986115
    [Abstract] [Full Text] [Related]

  • 45. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 46.
    Kobeissy FH, Toth A.
    ; 2015 Nov 24. PubMed ID: 26269902
    [Abstract] [Full Text] [Related]

  • 47. MicroRNA (miRNA) as a biomarker for diagnosis, prognosis, and therapeutics molecules in neurodegenerative disease.
    Alkhazaali-Ali Z, Sahab-Negah S, Boroumand AR, Tavakol-Afshari J.
    Biomed Pharmacother; 2024 Aug 24; 177():116899. PubMed ID: 38889636
    [Abstract] [Full Text] [Related]

  • 48. Magnetic resonance imaging monitoring of multiple sclerosis lesion evolution.
    Inglese M, Grossman RI, Filippi M.
    J Neuroimaging; 2005 Aug 24; 15(4 Suppl):22S-29S. PubMed ID: 16385016
    [Abstract] [Full Text] [Related]

  • 49. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL.
    Brain; 2019 Sep 01; 142(9):2787-2799. PubMed ID: 31497864
    [Abstract] [Full Text] [Related]

  • 50. Role of MRI in multiple sclerosis II: brain and spinal cord atrophy.
    Zivadinov R, Bakshi R.
    Front Biosci; 2004 Jan 01; 9():647-64. PubMed ID: 14766398
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. [Magnetic resonance imaging in multiple sclerosis].
    Tourbah A, Berry I.
    Pathol Biol (Paris); 2000 Mar 01; 48(2):151-61. PubMed ID: 10815291
    [Abstract] [Full Text] [Related]

  • 56. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 57. A mathematical model to predict the evolution of retinal nerve fiber layer thinning in multiple sclerosis patients.
    Montolío A, Cegoñino J, Orduna E, Sebastian B, Garcia-Martin E, Pérez Del Palomar A.
    Comput Biol Med; 2019 Aug 25; 111():103357. PubMed ID: 31326867
    [Abstract] [Full Text] [Related]

  • 58. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 25; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 59. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder.
    Ziemann U, Wahl M, Hattingen E, Tumani H.
    Prog Neurobiol; 2011 Dec 25; 95(4):670-85. PubMed ID: 21524682
    [Abstract] [Full Text] [Related]

  • 60. Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?
    Lee JY, Taghian K, Petratos S.
    Acta Neuropathol Commun; 2014 Aug 27; 2():97. PubMed ID: 25159125
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.